10-K: Fate Therapeutics Amends Collaboration Agreement with Ono, Increases R&D Budget

Fate Therapeutics and Ono Pharmaceutical Co., Ltd. have amended their collaboration agreement, increasing the estimated annual collaboration budget for research and development.

Summary

• Fate Therapeutics and Ono Pharmaceutical Co., Ltd. have amended their existing collaboration agreement, effective November 30, 2023.
• The amendment increases the estimated annual collaboration budget for a specific research term year by $[***].
• This change modifies the table of Annual R&D Fees in the original agreement.
• All other terms and conditions of the original agreement remain in full force and effect.

Sentiment

Score: 7

Explanation: The document indicates a positive development in an existing collaboration, with an increase in R&D funding, suggesting a continued commitment to the partnership. However, the lack of specific details and the absence of any discussion of future milestones or potential revenue generation limits the overall positive sentiment.

Positives

• The increased budget suggests continued investment and commitment to the collaboration.
• The amendment reinforces the ongoing partnership between Fate Therapeutics and Ono Pharmaceutical.

Risks

• The document does not provide details on the specific research activities or milestones associated with the increased budget.
• The financial impact of the increased budget on Fate Therapeutics' overall financials is not detailed.

Future Outlook

The document indicates a continued collaboration between Fate Therapeutics and Ono Pharmaceutical, with an increased budget for research and development activities.

Management Comments

• The document includes signatures from Scott Wolchko, President & Chief Executive Officer of Fate Therapeutics, Inc., and Toichi Takino, Member of the Board of Directors, Senior Executive Officer / Executive Director, Discovery & Research of Ono Pharmaceutical Co., Ltd.

Industry Context

This amendment reflects the ongoing trend of pharmaceutical and biotech companies collaborating to advance drug development, particularly in the field of cell therapies.

Comparison to Industry Standards

• Collaboration agreements between biotech and pharmaceutical companies are common, but the specific terms and financial details vary widely.
• The increase in R&D budget suggests a positive outlook for the collaboration, but the specific amount is not disclosed.
• Comparable agreements often include milestone payments, royalties, and profit-sharing arrangements, which are not detailed in this amendment.

Stakeholder Impact

• Shareholders may view the increased R&D budget as a positive sign of continued investment in the company's pipeline.
• Employees involved in the collaboration may benefit from the increased resources and focus on research and development.

Next Steps

• Fate Therapeutics and Ono Pharmaceutical will continue their research and development activities under the amended agreement.
• The companies will likely work towards achieving the milestones associated with the increased budget.

Key Dates

Keywords

Collaboration Agreement, Ono Pharmaceutical, Fate Therapeutics, R&D Budget, Research and Development, Amendment, iPSC, Cell Therapy